Nexon Joins Tesla in Bitcoin Bet With $100 Million Purchase

GlobeNewswire

Alcohol Addiction Pipeline Analysis: Key Pharma Companies Set to Develop Innovative Therapies and Explore Countless Opportunities

Alcohol Addiction Pipeline Insight report proffers rich insights into emerging Alcohol Addiction pipeline therapies with an analysis of 25+ key players and 25+ key therapies.Los Angeles, USA, April 27, 2021 (GLOBE NEWSWIRE) — Alcohol Addiction Pipeline Analysis: Key Pharma Companies Set to Develop Innovative Therapies and Explore Countless Opportunities Alcohol Addiction Pipeline Insight report proffers rich insights into emerging Alcohol Addiction pipeline therapies with an analysis of 25+ key players and 25+ key therapies. DelveInsight’s ‘Alcohol Addiction Pipeline Insights’ report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the Alcohol Addiction domain. Some of the key highlights of the Alcohol Addiction Pipeline report: Alcohol Addiction Pipeline report offers a comprehensive analysis of 25+ key players and 25+ key therapies.Out of all the emerging therapies, Ondansetron (ADial Pharmaceuticals), is expected to emerge as the trendsetter owing to reducing the cravings for alcohol to effectively curb alcohol intake. AD04 involves genetic screening with a companion diagnostic genetic test prior to treatment and uses a novel mode of action. Alcohol Addiction pipeline comprises Ondansetron (ADial Pharmaceuticals) in Phase III stage of clinical development, and Ibudilast (MediciNova) and GET-73 (CT Laboratories) in Phase II trial. PT 150 (Pop test oncology) is in Phase I study in collaboration with Baylor College of Medicine to assess pharmacokinetic interactions between ethanol (EtOH) and PT150 (900 mg qd) in non-treatment-seeking alcohol-experienced volunteers.Mapreg has planned to initiate a phase II trial for its lead candidate MAP4343, for Alcoholism in the USA in December 2021. The synthetic pregnenolone-derivative MAP4343 (3β-methoxy-pregnenolone) binds MAP-2 in vitro and has shown to increase its ability to stimulate tubulin assembly. Got queries? Want to know more? Request for Sample @ Alcohol Addiction Emerging Therapies and Forecast The report lays down a complete coverage of the therapeutics by development stage, product type, and route of administration, molecule type, and MOA type for Alcohol Addiction across the complete product development cycle, including all clinical and non-clinical stages. The Alcohol Addiction pipeline report puts on the table business opportunities, threats, prospective collaborations, strong competitors, growth strategies, and failed as well as discontinued drugs. Alcohol Addiction: Overview Alcohol addiction or alcoholism affects people worldwide. Addiction to alcohol can lead to several changes ranging from psychological, genetic, and behavioral factors. The condition results in changes to the brain and neurochemistry and a person often lose the sense of control. For more information on emerging drugs, visit Alcohol Addiction Pipeline Analysis Alcohol Addiction Pipeline Drugs DrugCompanyClinical PhaseMoARoAOndansetron ADial PharmaceuticalsIIISerotonin 3 receptor antagonistsOralIbudilast MediciNovaIINitric oxide synthase inhibitors; Phosphodiesterase 10A, 11 A inhibitors; Type 3, 4 cyclic nucleotide phosphodiesterase inhibitorsNAGET-73 CT LaboratoriesIIMetabotropic glutamate receptor 5 antagonistsOralOPNT002Opiant PharmaceuticalsIIOpioid receptor antagonistsIntranasalMifepristoneCorcept TherapeuticsIIGlucocorticoid receptor antagonists; Progesterone receptor antagonistsOralKT 110Kinnov TherapeuticsIISerotonin 2 receptor antagonistsOralBXCL501BioXcel TherapeuticsIAlpha 2 adrenergic receptor agonistsOralPT 150Pop Test OncologyIAndrogen receptor antagonists; Glucocorticoid receptor antagonistsNANaltrexone controlled-releaseBioCorRxPreclinicalOpioid receptor antagonistsNACannabidiolZynerbaPharmaceuticalsPre-clinicalSerotonin 1 receptor modulatorsNANezavistLohocla ResearchPreclinicalGABA receptor agonists; Glutamate antagonists; NMDA receptor antagonistsNATNX-102Tonix PharmaceuticalsPreclinicalAlpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Serotonin 2A receptor antagonistsNADCR AUDDicerna PharmaceuticalsPreclinicalAldehyde dehydrogenase 2 inhibitors; RNA interferenceNA Request for Sample to know more @ Alcohol Addiction Pipeline Analysis, Key Companies and Futuristic Trends Alcohol Addiction Therapeutic Assessment The Alcohol Addiction Pipeline report proffers exhaustive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs. By Product Type MonoCombination By Stage Discovery Pre-clinicalINDPhase IPhase IIPhase IIIPre-registration By Molecule Type Small Molecule Gene TherapyStem Cell Therapy By Route of Administration IntravenousInhalationOralSubcutaneous By Mechanism of Action Serotonin 2A receptor antagonistsGlucocorticoid receptor antagonists; Progesterone receptor antagonistsGABA receptor agonists; Glutamate antagonists; NMDA receptor antagonistsOpioid receptor antagonists By Targets Protease Multiple Kinase By Stage and Route of AdministrationBy Stage and Product Type Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions Scope of the Report Coverage: GlobalKey Players: Pop Test Oncology, Zynerba Pharmaceuticals, MediciNova, CT Laboratories, ADial Pharmaceuticals, BioXcel Therapeutics, Opiant pharmaceuticals, Astrea Therapeutics, Corcept Therapeutics, BioCorRx, Kinnov Therapeutics, Lohocla Research, Avicanna, Tonix pharmaceutical, Dicerna Pharmaceuticals, Choronos Therapeutics, Montipharma, Orphomed Inc, Mapreg and others. Key Alcohol Addiction Pipeline Therapies: PT 150, Cannabidiol, Ibudilast, GET-73, Ondansetron, BXCL501, OPNT002, AT-121, Mifepristone, Naltrexone controlled-release, KT 110, Nezavist, TNX-102, DCR AUD, MAP4343 and others Reach out @ Alcohol Addiction Pipeline: Novel therapies and emerging technologies Table of Contents 1Introduction2Executive Summary3Alcohol Addiction Overview4Alcohol Addiction Pipeline Therapeutics5Alcohol Addiction Pipeline Therapeutic Assessment6Alcohol Addiction – DelveInsight’s Analytical Perspective7In-depth Commercial Alcohol Addiction Pipeline Assessment8Alcohol Addiction Collaboration Deals9Late Stage Alcohol Addiction Pipeline Products (Phase III and Preregistration)10Mid-Stage Alcohol Addiction Pipeline Products (Phase II)11Pre-clinical and Discovery Stage Alcohol Addiction Pipeline Products12Inactive Alcohol Addiction Pipeline Products13Alcohol Addiction Key Companies14Alcohol Addiction Key Products15Alcohol Addiction Unmet Needs16Alcohol Addiction Market Drivers and Barriers17Alcohol Addiction Future Perspectives and Conclusion18Alcohol Addiction Pipeline Analyst Views20Appendix Visit to know more of what’s covered @ Alcohol Addiction Emerging Therapies Related Reports ABSSSI Market Read more about key companies and pipeline therapies in the ABSSSI Market. Angelman Syndrome MedicationsComprehensive analysis of Angelman Syndrome Medications, available and emerging, in the Angelman Syndrome Medications Market. Boehringer Ingelheim PipelineKnow more about the Pipeline development of the Boehringer Ingelheim. Argininosuccinic Aciduria MarketDelveInsight’s “Argininosuccinic Aciduria (ASA) – Market Insights, Epidemiology, and Market Forecast –2030” report. Arteriovenous Fistula MarketDelveInsight’s “Arteriovenous fistula – Market Insights, Epidemiology, and Market Forecast-2030” report. Artificial Pancreas Device System MarketDelveInsight’s “Artificial Pancreas Device System – Market Insights, Epidemiology, and Market Forecast-2030” report. Central Serous Chorioretinopathy MarketDelveInsight’s “Central Serous Chorioretinopathy Market Insights, Epidemiology, and Market Forecast-2030” report. Cataplexy MarketDelveInsight’s “Cataplexy Market Insights, Epidemiology, and Market Forecast-2030” report. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare and Biotech News CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com